03:25 AM EDT, 07/17/2026 (MT Newswires) -- The European Commission granted marketing authorization for Boehringer Ingelheim's Jascayd treatment for adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in May, according to a Friday release. The positive opinion was based on results from the Fibroneer phase 3 clinical trial program.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.